Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized controlled phase III RECOVER trial of GS010 for Leber's Hereditary Optic Neuropathy (LHON)

Next Previous
Trial Profile

A randomized controlled phase III RECOVER trial of GS010 for Leber's Hereditary Optic Neuropathy (LHON)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 20 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenadogene nolparvovec (Primary)
  • Indications Leber's hereditary optic atrophy
  • Focus Therapeutic Use
  • Acronyms RECOVER

Most Recent Events

  • 12 Jun 2025 According to GenSight Biologics media release, the company plans to hold a pre-submission meeting with the MHRA in early H2 2026.
  • 12 Jun 2025 According to GenSight Biologics media release, the company plans to complete Phase III trial preparations in Q2 2026 and initiate the global Phase III clinical trial in early H2 2026.
  • 07 Apr 2025 According to GenSight Biologics media release, company is focusing on kicking off RECOVER Phase III trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top